President

Transcript : BioCryst Pharmaceuticals, Inc. Presents at Cantor Global Healthcare Conference 2025, Sep-04-2025 09

Closing treatment gaps in yellow fever: are germ-free egg-based vaccines the answer?

In Crowded Market for a Rare Disease, Ionis Bets Patients Will Switch to Its New First-in-Class Drug

Ionis steps into crowded HAE market with FDA approval for Dawnzera

VP, Global Regulatory Affairs

BioCryst Pharmaceuticals is dedicated to improving the lives of individuals with rare diseases through innovative drug development. The VP, Global Regulatory Affairs will lead regulatory strategies, ensuring compliance and collaboration with senior leadership to support clinical programs and product development initiatives.

Director, Global Talent Management

Chief People Officer

Vice President Intellectual Property

Executive Director, Regulatory Affairs

Sr. Manager, Global Regulatory Affairs Labeling

Sign up with Google

Sign in with Google